Covid-19: the Cargo community of Paris-CDG is mobilised and ready to transport future vaccines

The ACFA explained to the press on 24 November that the Cargo community of Paris-Charles de Gaulle Airport has made every effort to prepare for the immediate transportation and distribution of the future vaccines against Covid-19 as soon as they are authorised and able to be distributed.

Since the beginning of the health crisis, Groupe ADP and the players of the air cargo and logistics sectors at Paris-Charles de Gaulle have been very active in ensuring the continuity of the cargo business and in transporting food and goods considered essential for France’s economy, including medical equipment and supplies, food, as well as components and spare parts for the industry.

Over the last few years, Groupe ADP has set up sectors of excellence. As a result, several major operators based in the Cargo City of Paris-Charles de Gaulle obtained the CEIV Pharma certification, which will certainly have an important impact given the current context


Covering 300 hectares and 700,000 sq.m of cross-dock warehouse areas with direct access to the airport’s security area, the Cargo City at Paris-Charles de Gaulle Airport is a significant asset to help all members of the cargo community and their loaders reduce the delay between the delivery of the vaccines and their shipment to the distribution sites.
Edouard Mathieu
Director of development at Paris-Charles de Gaulle Airport

Focus on the CEIV Pharma certification

The CEIV Pharma certification is conferred by the International Air Transport Association (IATA) to companies able to meet the requirements of pharmaceutical manufacturers. It guarantees that the premises, facilities, activities and staff comply with all the norms, regulations and national and international directives in place to protect the integrity of time-sensitive products requiring controlled temperatures, such as vaccines, up to their final destination.

This certification takes account of the IATA temperature control regulations, the distribution best practices of the European Union, the World Health Organization (WHO) recommendations, and United States pharmacopoeia norms. According to IATA, the CEIV Pharma certification has helped reduce the number of non-conformities for pharmaceutical acceptance by 45%.